MindMed Provides Status Update on IND for Phase 2b Trial of

- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder -
NEW YORK, Dec. 21, 2021 /PRNewswire/ --... | December 21, 2021

Related Keywords

Germany , Canada , Canadian , Robert Barrow , Exchange Commission , National Institute Of Mental Health , Drug Administration , Prnewswire Mind Medicine Mindmed Inc , Nasdaq , Medicine Mindmed Inc , Chief Executive Officer , National Institute , Mental Health , Major Depressive Disorder , Mind Medicine Mindmed Inc Stock Exchange , News , Information , Press Release , Fda , Gas , Ssued , Linical , Gold , N , Nitial , End , Submission , Equired , O , Nitiate , Hase , Tb , Trial , F , Sd , Or , The , Treatment , Generalized , Anxiety , Disorder , Few , 021 Mnmd Ca60255c1095 ,